TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03348306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Brain and cardiac MRI in one time with gadolinium injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: A blood sampling is also collected for hematocrit measure.
Study: NCT05125640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)
Description: Orally, with 240 mL of water at dosing in sitting position

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Utrogestan® 200 mg Soft Capsule (Manufacturer by: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)
Description: Orally, with 240 mL of water at dosing in sitting position
Study: NCT02531048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser stimulations on lower limbs
Description: 20 laser stimulations for each site : back foot, outer face of the legs, and anterior thigh

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser stimulations cervical
Description: 15 laser stimulations cervical areas below the ears.
Study: NCT04528719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Formulation for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT03314064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: DTG is an integrase inhibitor that has been developed for ART of HIV-infection in combination with other antiretrovirals. DTG will be available as 50 mg tablets to be administered once daily.
Study: NCT03088488

Intervention type: DIAGNOSTIC_TEST
Intervention: fasting venous blood samples

Intervention type: DIAGNOSTIC_TEST
Intervention: fasting venous blood samples
Study: NCT03433417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera truSculpt
Description: One truSculpt treatment delivered 0 to 90 days before scheduled Abdominoplasty to one side of the tissue to be removed during abdominoplasty
Study: NCT04320784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
Study: NCT03627728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: regorafenib/placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: regorafenib/placebo
Study: NCT04126291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of whiteboard videos
Description: Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived self-efficacy/confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
Study: NCT02420028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of OptiVein IV catheter
Description: Placement of OptiVein IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of Vasofix Certo IV catheter
Description: Placement of Vasofix Certo IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
Study: NCT04122573

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary angiography
Description: Acute chest pain patients, suspected acute coronary syndrome, are diagnosed by coronary angiography.

Intervention type: DIAGNOSTIC_TEST
Intervention: CT angiography of aorta
Description: Acute chest pain patients, suspected acute aortic dissection, are diagnosed by gold standard of CTA.

Intervention type: DIAGNOSTIC_TEST
Intervention: CT angiography of pulmonary arteries.
Description: Acute chest pain patients, suspected acute pulmonary embolism, are diagnosed by gold standard of CTA.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: All patients with acute chest pain will subject to ECG examination within 10 minutes of admission, which can quickly screen ST-segment elevation myocardial infarction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Troponin
Description: Dynamic changes of cardiac troponin I and/or T will be used in the diagnosis of acute myocardial infarction
Study: NCT00847275

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exclusive nephrology follow-up
Description: 250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric follow-up
Description: 250 patients will be included and randomized in geriatric follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. Patients randomized in the geriatric follow-up arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status.
Study: NCT00443183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview (BNI)
Description: The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Discharge Instructions
Description: Used as a placebo comparator, scripted discharge instructions are to be read by emergency practitioner and designed to be less than 1 minute in length.
Study: NCT02847793

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaze training
Description: Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial. (A total of 576 trials will be distributed in a 2-day intervention).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Participants are exposed to the same amount of time to the experimental stimuli used in the experimental group but there is no contingency between participants' gaze patterns and the end of each of the 576 trials.
Study: NCT00515827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (MK-0518)
Description: 400 mg tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (MK-0518)
Description: 400 mg tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 400 mg placebo tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 400 mg placebo tablet taken orally twice daily
Study: NCT02327923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.
Study: NCT05248581

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: living donor liver transplantation
Study: NCT04661007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafasitamab
Description: tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafasitamab
Description: tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafasitamab
Description: tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafasitamab
Description: tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: lenalidomide will be administered orally at protocol defined timepoints based on the groups participants are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: lenalidomide will be administered orally at protocol defined timepoints based on the groups participants are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered at protocol defined timepoints based on the groups participants are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered at protocol defined timepoints based on the groups participants are assigned.
Study: NCT02327923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Inj. Paracetamol 1 gm IV at the time of induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Inj. Paracetamol 1 gm IV at the time of induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Inj. Propofol 2- 2.5 mg/kg will be given for induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Inj. Propofol 2- 2.5 mg/kg will be given for induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Inj fentanyl 1.5mg/kg will be given at the time of induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Inj fentanyl 1.5mg/kg will be given at the time of induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium
Description: Inj Vecuronium 0.1mg/kg will be given at induction and for maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium
Description: Inj Vecuronium 0.1mg/kg will be given at induction and for maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Inj Atropine 0.4 mg IV will be given for bradycardia (HR \< 50/min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Inj Atropine 0.4 mg IV will be given for bradycardia (HR \< 50/min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Study: NCT01220921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Discectomy
Description: Microsurgical removal of disc that is compressing a nerve root

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-level lumbar fusion
Description: pedicle screws with arthrodesis as directed by surgeon. Fusion can be posterolateral, interbody, or both.
Study: NCT02501642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concussion Coach
Description: smart phone app with educational material on postconcussion symptoms and behavioral self-monitoring/strategies

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual
Study: NCT01303159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic bipolar radiofrequency probe (ENDOHPB)
Description: EndoHPB (EMcision Ltd, UK) is a single use sterile device for use at ERCP or PTC. It is a 8F (2.6mm) catheter with a 1.8m working length, that is designed to be inserted into the target duct of the hepatic, biliary or pancreatic system over a guide wire. The device is compatible with endoscopes that have a working channel of 3.2mm or greater. It comprises of a coaxial over the wire (OTW) catheter with 2 ring electrodes spaced 8mm apart at its distal end. The distal electrode is 5mm from the leading edge of the catheter. The two electrodes at the distal end of EndoHPB are designed to produce a heating zone length of approximately 25 mm.
Study: NCT04661007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. R-CHOP will be administered at protocol defined timepoints based on the groups participants are assigned.
Study: NCT02586727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aflibercept
Description: This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.
Study: NCT02070718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Dose Kappa Agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half Dose Kappa Agonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01610726

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced versus conventional recovery in colorectal surgery
Description: Enhanced recovery (extended informations to the patients, change of anesthetic procedure, intravenous versus gas, and intensified mobilisation) versus conventional recovery
Study: NCT00131027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3 g/sqm (high dose)
Study: NCT00131027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 0.5 g/sqm (intermediate dose)
Study: NCT00762281

Intervention type: DEVICE
Group type: OTHER
Intervention: MEL 80 Hyperopic LASIK Treatment
Description: Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
Study: NCT04772456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\].
Study: NCT02106715

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Two exercises for training of core stability and mobility.
Study: NCT02928198

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABSORB BVS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABSORB BVS
Study: NCT00902590

Intervention type: OTHER
Intervention: saliva sample and questionaire
Description: Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have undergone germline sequencing as part of Protocol 12-245, they will not need to provide a buccal sample. If the cases have previously completed athe the Urothelial Baseline Questionnaire, in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire.

Intervention type: OTHER
Intervention: saliva sample, questionaire
Description: Urothelial Cancer Registry- These participants will be requested to complete the risk factor questionnaire and to provide a saliva sample for DNA extraction.
Study: NCT01451177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured dermal and epidermal cells
Description: A piece of occipital scalp, plucked of hairs prior to excision, is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. The cells are then injected into the balding area of the scalp of the original subject.
Study: NCT02643121

Intervention type: OTHER
Intervention: therapy sepsis
Description: Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage
Study: NCT03028324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
Study: NCT01560806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Commune Hypertension Management
Description: People with high blood pressure will be invited to join the management programme, with monthly check-up, delivery of multi anti-hypertensive drugs and lifestyle consultation.~Antihypertensive drugs delivered to local patients included (1) low-dose hypothiazide diuresis, (2) calcium channel blocker and (3) ACEI
Study: NCT03534817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Access CR
Description: Participants in the Early Access CR group will begin CR within 1-week post-hospital discharge following their MI, as opposed to Standard Access CR group which begins 7-weeks post-hospital discharge, and the Canadian average (10-14 weeks post-hospital discharge). No further intervention or differentiation between groups is applied; the actual CR program is standardized between groups, and follows the guidelines regularly practiced by the institution.